256 related articles for article (PubMed ID: 20425441)
1. Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Oh ST; Gotlib J
Curr Hematol Malig Rep; 2008 Jan; 3(1):10-8. PubMed ID: 20425441
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenesis in myelodysplastic syndrome.
Aguayo A; Armillas-Canseco FM; Martínez-Baños D
Curr Cancer Drug Targets; 2011 Nov; 11(9):1044-52. PubMed ID: 21999628
[TBL] [Abstract][Full Text] [Related]
3. Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib J; Greenberg PL
J Natl Compr Canc Netw; 2003 Oct; 1(4):473-80. PubMed ID: 19774739
[TBL] [Abstract][Full Text] [Related]
4. New approaches to the treatment of myelodysplasia.
List AF
Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
[TBL] [Abstract][Full Text] [Related]
5. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
Aguayo A
Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of lenalidomide in hematological malignancies.
Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
[TBL] [Abstract][Full Text] [Related]
9. [Lenalidomide in hematological malignancies---review].
Jin X; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
Dreicer R
Curr Oncol Rep; 2007 Mar; 9(2):120-3. PubMed ID: 17288877
[TBL] [Abstract][Full Text] [Related]
12. Translational research in myelodysplastic syndromes.
Raza A; Qawi H; Mehdi M; Mumtaz M; Galili N
Rev Clin Exp Hematol; 2004 Dec; 8(2):E2. PubMed ID: 16027100
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy in hematologic malignancies.
Moehler TM; Hillengass J; Goldschmidt H; Ho AD
Curr Pharm Des; 2004; 10(11):1221-34. PubMed ID: 15078137
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS; List AF
Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
[TBL] [Abstract][Full Text] [Related]
17. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J; List A
Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
[TBL] [Abstract][Full Text] [Related]
20. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
